Real-World Data Linkage Research Platform
This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.
In parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.
Overall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.
연구 개요
상태
상세 설명
This multicenter, observational cohort study aims to integrate longitudinal health data from China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to address key data challenges in the medical domain, particularly in chronic diseases and suboptimal health status. It is driven by two primary objectives:
- Intelligent and automated data governance To ensure high data quality, the platform will engineer a self-adaptive, automated governance intelligent agent. Integrating Large Language Models (LLMs) and High-Order Programming (HOP), this agent actively monitors and corrects real-world data issues, such as missing values, redundancies, and formatting inconsistencies. Through deep learning, the agent continuously optimizes its governance rules to adapt to complex medical data environments.
- Trusted and secure data sharing To facilitate multicenter collaborative research, the study will establish a secure and trusted data-sharing framework. By integrating AI confidential computation (AICC) with Trusted Data Matrix (TDM) technologies, the platform provides hardware-level security guarantees. This ensures that real-time, cross-institutional data exchange and collaborative computation without exposing sensitive patient information.
Overall Objective The platform aims to transform heterogeneous clinical data into standardized, high-quality, and securely accessible resources, thereby enabling efficient data utilization and promoting the value circulation of medical data for real-world evidence research.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Yuanyuan Kong, PhD
- 전화번호: +86 1063139362 +86 15810026760
- 이메일: kongyy@ccmu.edu.cn
연구 연락처 백업
- 이름: Hao Wang, PhD
- 전화번호: +86 1063139363 +86 18301250922
- 이메일: hao.wang@mail.ccmu.edu.cn
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100050
- Beijing Friendship Hospital, Capital Medical University.No. 95, Yongan Road, Xicheng District, Beijing, 100050, China
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
This study establishes a multicenter, observational real-world data platform integrating longitudinal health data from multiple sources across China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to support population-level research without restriction to specific diseases or conditions, enabling inclusive and continuous assessment of health status, disease risk, progression, and outcomes in real-world settings.
All available individuals with usable health-related data are eligible for inclusion, with minimal restrictions to maximize data coverage and representativeness. Both retrospective and prospective data will be incorporated and linked at the individual level using standardized protocols within a secure data governance and privacy protection framework.
설명
Inclusion Criteria:
Participants will be eligible for inclusion if they meet all of the following criteria:
- Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status.
- Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information.
- Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources.
Exclusion Criteria:
Participants or records meeting any of the following criteria will be excluded:
- Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information).
- Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events.
- Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Data-Link Cohort
The study cohort is derived from a multicenter, population-based real-world data platform that integrates longitudinal data from electronic medical records, disease registries, and routine health examinations across multiple institutions.
The platform is designed to support broad, disease-agnostic research and enable dynamic evaluation of health status, disease risk, and outcomes in real-world settings.
|
This is an observational study.
No intervention will be applied.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Accuracy Rate of Automated Data Governance
기간: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data accuracy will be evaluated by measuring the proportion of data values that correctly match the gold-standard reference after automated data governance.
The accuracy rate will be calculated as the percentage of correctly recorded or corrected data elements among all evaluated data elements.
Values range from 0% to 100%, with higher values indicating better data accuracy.
|
2026.5.30 to 2028.12.31
|
|
Completeness Rate of Automated Data Governance
기간: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data completeness will be evaluated by measuring the proportion of required data fields that are complete after automated data governance.
The completeness rate will be calculated as the percentage of non-missing required data elements among all required data elements.
Values range from 0% to 100%, with higher values indicating better data completeness.
|
2026.5.30 to 2028.12.31
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correction Accuracy of Automated Data Governance
기간: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in resolving identified data quality issues will be evaluated by measuring correction accuracy.
Correction accuracy will be calculated as the percentage of identified data quality issues (e.g., missing values, format inconsistencies, and logical conflicts) that are correctly resolved after automated data governance, compared with the gold-standard reference dataset.
Values range from 0% to 100%, with higher values indicating better correction performance.
|
2026.5.30 to 2028.12.31
|
|
Data Standardization Rate of Automated Data Governance
기간: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in standardizing data will be evaluated by measuring the proportion of data elements that conform to predefined data standards, terminologies, and formatting rules after automated data governance.
The data standardization rate will be calculated as the percentage of evaluated data elements that meet standardized data specifications among all assessed data elements.
Values range from 0% to 100%, with higher values indicating better data standardization.
|
2026.5.30 to 2028.12.31
|
|
Cross-institutional Data Usability of Automated Data Governance
기간: 2026.5.30 to 2028.12.31
|
Using datasets derived from participating institutions, the effectiveness of the intelligent agent in improving cross-institutional data usability will be evaluated by measuring the proportion of governed datasets that can be successfully integrated, interpreted, and used across different institutions according to predefined interoperability and usability criteria after automated data governance.
Cross-institutional data usability will be calculated as the percentage of datasets meeting prespecified usability criteria among all evaluated datasets.
Values range from 0% to 100%, with higher values indicating better cross-institutional usability.
|
2026.5.30 to 2028.12.31
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yuanyuan Kong, Beijing Friendship Hospital
간행물 및 유용한 링크
일반 간행물
- D. Reddy, "Data Engineering Challenges in AI automation," 2023 International Conference on Computing, Electronics & Communications Engineering (iCCECE), Swansea, United Kingdom, 2023, pp. 107-112
- Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer AM. An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin. 2022 May;72(3):287-300. doi: 10.3322/caac.21714. Epub 2021 Dec 29.
- Kam K.H. Ng, Chun-Hsien Chen, C.K.M. Lee, Jianxin (Roger) Jiao, Zhi-Xin Yang; A systematic literature review on intelligent automation: Aligning concepts from theory, practice, and future perspectives; Advanced Engineering Informatics; 2021 January; Volume 47; 101246
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Data-Link
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 질환에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인
-
University of Pennsylvania완전한Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410의 주진단 또는 이차진단 코드가 있는 환자(5번째 숫자가 2인 경우 제외)미국